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cancer or severe renal failure. The patients under-
went an extensive social and clinical evaluation. 
The instrumental assessment provided data regard-
ing cardiac structures and left ventricular perfor-
mance, common carotid artery intima–media 
thickness and wall motion, and aortic pulse wave 
velocity. Atrial arrhythmias had a prevalence of 
25%. The follow-up was completed in April 2004. 
After approximately 1 year (mean length of follow-
 up: 380 days), 33% of patients had died. The 
authors demonstrated that the presence of an atrial 
arrhythmia at baseline was signi ficantly correlated 
with mortality, entailing a risk of dying two-times 
higher than that observed in sinus rhythm patients 
(relative risk: 2.40; 95% CI: 1.41–4.07). This asso-
ciation was so strong that it persisted even after 
adjustment for age, gender and the presence of 
lower values of diastolic blood pressure and in a 
series of multivariable models with progressively 
increasing complexity, including almost all of the 
most important social, clinical and laboratory 
variables (i.e., educational level, neuropsycho-
logical function, reason for hospitalization, main 
comorbid ities, drug therapy, some metabolic indi-
cators and parameters associated with vascular and 
cardiac function). Only when the models were 
adjusted for structural cardiac parameters was 
the independent predictive value of atrial arrhyth-
mia on mortality lost, being then replaced by left 
atrium diameter.
Discussion
The results obtained by Vesin and colleagues are 
of great interest, even though they seem to be 
in conflict with the findings of some important 
studies. In fact, the Atrial Fibrillation Follow-up 
Investigation of Rhythm Management (AFFIRM) 
In a recent study, Vesin and colleagues demon-
strated that the presence of an atrial arrhythmia 
found in a standard 12-lead resting ECG in a hos-
pitalized elderly population was an independent 
predictor of all-cause mortality during follow-
up [1]. This result is particularly intriguing from 
a geriatric point of view if we consider that atrial 
fibrillation (AF) and flutter, which are very simi-
lar [2] and are often considered clinical signatures 
of the aging process [3], were the most represented 
types of arrhythmia, with atrial tachycardia being 
diagnosed in only a minority of cases [1]. The close 
link between age and AF was recently confirmed 
in the Framingham Study, in which it was found 
that the 10-year risk for developing arrhythmia 
increased from approximately 15% in subjects 
younger than 65 years to 27% in subjects older 
than 65 years [4]. From an economic point of 
view, AF represents a significant health problem 
since it is responsible for 350,000 hospitalizations, 
5 mill ion office visits, 276,000 emergency depart-
ment visits and 234,000 outpatient visits each year 
in the USA alone, with a total estimated cost of 
US$6.65 billion [5]. 
Summary of methods & results
The Vesin et  al.  study included 331 consecu-
tive patients aged older than 70 years (mean 
age: 85 years) with a history of cardiovascular dis-
ease, who were admitted to the geriatric department 
of two French hospitals involved in the Pronostic 
Cardiovasculaire et Optimisation Therapeutique 
en Geriatrie (PROTEGER) study between May 
2000 and November 2001. Exclusion criteria were 
the presence of severely impaired cognitive status 
(Mini Mental State Examination <15), fatal illness 
(life expectancy <1 month), cachexia, advanced 
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investigators demonstrated that no survival benefit 
was associated with a rhythm-control strategy for 
AF when compared with rate-control in a large 
series of patients aged 70 years at a high risk for 
stroke and death [6]. Similarly, no difference in 
mortal ity between these two types of treatment 
was observed in patients aged 67 years with a 
history of AF and congestive heart failure (left 
ventricular ejection fraction ≤35%), who were 
enrolled in the Atrial Fibrillation in Congestive 
Heart Failure (AF-CHF) trial [7]. The results of 
these studies appear to suggest that the clinical 
impact of AF is negligible when an optimal con-
trol of heart rate is reached. How can we explain 
these apparently conflicting results? They are 
probably due to the clinical characteristics of the 
populations studied. In fact, as Vesin and col-
leagues acknowledge in the discussion section of 
their article, their dataset consisted of very old 
and complex subjects with a history of cardio-
vascular disease and with a medical condition 
severe enough to require hospitalization [1]. The 
main clinical causes of admission to the hospital 
in this ‘real-world’ geriatric population, along with 
cardiovascular diseases (19%), were falls (36%), 
dementia or neuropsychological problems (14%) 
and infections (10%). Medical conditions were 
so severe that 1-year mortality was approximately 
33%, while it was only 4 and 10% in the AFFIRM 
and the AF-CHF trials, respectively [1,6,7].
Moreover, the presence of AF greatly influences 
many important aspects of geriatric medicine 
apart from mortality. First, in the Rate Control 
Versus Electrical Cardioversion (RACE) study, 
the health-related quality of life (HRQL), assessed 
with the generic instrument SF-36, was impaired 
in patients with arrhythmia when compared with 
healthy controls. After a follow-up of 2.3 years, the 
persistence of sinus rhythm was associated with 
a significant improvement in HRQL [8]. These 
results were further strengthened by the Sotalol 
Amiodarone Atrial Fibrillation Efficacy Trial 
(SAFE-T), which demonstrated that cardio version 
significantly enhances HRQL in the absence of 
arrhythmia relapses [9]. Mood disorders are also 
important in subjects with arrhythmia. In fact, 
the presence of depressive symptoms predicted 
cardiovascular and all-cause mortality in the 
AF-CHF trial patients, with adjusted hazard 
ratios of 1.57 (95% CI: 1.20–2.07) and 1.38 
(95% CI: 1.07–1.77), respectively [10]. However, 
the most fascinating aspect related to AF in the 
elderly is the association between the arrhyth-
mia and cognitive decline. It was first reported 
by the investigators of the Rotterdam Study who 
demonstrated that both vascular and Alzheimer’s 
dementia may be determined by AF, even in the 
absence of a history of stroke [11]. More recently, 
in the 2837 patients with AF enrolled in the 
Olmsted County Study (mean age: 71 years), it 
was found that the rate of dementia was 2.7% over 
the first year of follow-up and approximately 2.0% 
per year thereafter, with a cumulative event-rate 
that reached 10.5% at 5 years [12]. Moreover, the 
difference in the incidence of dementia between 
AF patients and normal subjects was particu-
larly evident at advanced age (i.e., 80–84 years 
of age; AF patients: 58.3 and 55.8 per 1000 
person/year event-rate for men and women, 
respectively vs normal subjects: 28.1 and 
24.7 per 1000 person/year event-rate for men 
and women, respectively) [12]. The association 
between AF and dementia could be explained 
by the observation that the presence of a micro-
vascular disease and the activation of the meta-
bolic cascade leading to inflammation are typical 
features of both conditions [13–15]. 
Finally, some conclusions can be drawn from 
the study regarding the clinical setting in which 
the arrhythmia develops. In fact, AF often repre-
sents a comorbid condition; in this case, the main 
diagnosis is almost always a common geriatric 
Executive summary
• The prevalence of atrial fibrillation (AF) increases with age; for this reason, the arrhythmia is often considered a clinical signature of the 
aging process.
• The presence of an atrial arrhythmia (usually AF) in a hospitalized frail elderly population is an independent predictor of all-cause 
mortality during follow-up.
• AF is linked with inflammation.
• AF is correlated with with stroke and heart failure.
• New findings associate AF with worsening health-related quality of life, depression and dementia.
• The increased incidence of AF complications in the elderly may explain the different clinical course of arrhythmia in older compared 
with yonger individuals.
• AF might represent a marker of frailty in older subjects.
• New, specifically age-oriented guidelines are necessary in order to effectively manage AF in elderly patients. 
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clinical problem, such as chronic heart failure, 
pneumonia, non-ST segment elevation myocardial 
infarction, chronic obstructive pulmonary disease, 
stroke or urinary incontinence [5]. Accordingly, 
the results obtained in the 23,174 hospital-
ized patients enrolled in the Gruppo Italiano 
di Farmacoepidemiologia nell’Anziano (GIFA) 
study demonstrated that the prevalence of AF 
as a comorbid condition underwent a sharp age-
related increase [16]. AF patients were older, more 
frequently disabled and characterized by a greater 
comorbidity and a longer in-hospital length of stay. 
Moreover, their urea nitrogen concentration was 
higher, while total cholesterol was lower. Finally, 
in-hospital mortality was slightly but significantly 
greater in subjects with AF (7.1 vs 6.0% in sinus 
rhythm patients, p < 0.001) [16]. Therefore, it is not 
surprising that patients who died during follow-
up in the study by Vesin and colleagues displayed 
not only an increased prevalence of arrhythmias at 
baseline, but also lower body weight and diastolic 
blood pressure and a higher left atrial diameter [1].
Future perspective
Previous evidence linking AF with stroke or wors-
ening heart failure, and new findings linking AF 
with HRQL, dementia and mortality, appear to 
indicate that the clinical burden of AF is greater 
in the elderly, in whom arrhythmia may represent 
a marker of frailty [16]. Based on this, in the near 
future, geriatricians should draw their own guide-
lines for the management of AF in older patients. 
Do we practice geriatric cardio logy? At least for 
AF, this 13 year-old question is still legitimate [17].
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